01—Abstract
Summary
Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported second-quarter 2024 net sales of $807 milliona, down 5% overall and down 4% organically, against $846 million a year earlier.
Reported diluted EPS rose to $1.86b from $1.82, while adjusted diluted EPS fell 6% to $2.06. Gross margin increased 70 bps to 45.4%, driven mainly by price/cost and operational productivity, while adjusted EBITDA margin declined 60 bps to 27.8%, reflecting lower volume leverage and unfavorable mix. Operating cash flow was $134 million, down 5%, and free cash flow was $118 million, down 2%.
The Health & Science Technologies segment, with organic net sales down 11%c, was the main source of weakness, while Fluid & Metering Technologies was flat organically and Fire & Safety/Diversified Products rose 1%. The company lowered its full-year 2024 outlook. Organic sales are now projected to decline 1% to 2%, versus prior guidance of an increase of 0% to 2%.
GAAP diluted EPS guidance is $6.85 to $6.95d (adjusted $7.80 to $7.90), down from $7.13 to $7.43 (adjusted $8.15 to $8.45). For the third quarter, organic sales are projected to be 0% to 1% higher year over year, with GAAP diluted EPS of $1.61 to $1.66 and adjusted diluted EPS of $1.85 to $1.90. Management cited uncertainty-fueled macro headwinds and project delays in industrial markets, and noted that the Semiconductor and Life Sciences & Analytical Instrumentation markets have not yet launched a recovery.
On capital deployment, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation and its subsidiaries for $1.0 billion in cash, subject to customary adjustments, with closing expected by the end of the third quarter of 2024. The company also divested Alfa Valvole Srl for $45.5 million in cash, recognizing a gain of $4.6 million, and repaid $25.0 million of the $50.0 million outstanding under its term facility. Cash and cash equivalents were $700.7 million at June 30, 2024, compared with $534.3 million at December 31, 2023.
02—Key points
Key Highlights
- Q2 2024 net sales of $807 million, down 5% overall and 4% organically; adjusted diluted EPS of $2.06, down 6%, which the company said exceeded its second-quarter expectations.
- Full-year 2024 organic sales growth now projected to decline 1% to 2%, down from prior guidance of an increase of 0% to 2%.
- Full-year GAAP diluted EPS guidance lowered to $6.85 to $6.95 (adjusted $7.80 to $7.90), from $7.13 to $7.43 (adjusted $8.15 to $8.45).
- Gross margin rose 70 bps to 45.4%, while adjusted EBITDA margin fell 60 bps to 27.8% on lower volume leverage and unfavorable mix.
- Health & Science Technologies organic net sales fell 11% on broad-based market softness, while Fluid & Metering Technologies was flat organically and Fire & Safety/Diversified Products rose 1%.
- Agreement to acquire Mott Corporation for $1.0 billion in cash, with closing expected by the end of the third quarter of 2024.
- Divested Alfa Valvole Srl for $45.5 million, recognizing a $4.6 million gain; repaid $25.0 million under the term facility.
03—Questions
Frequently Asked Questions
How did IDEX perform in the second quarter of 2024?
Net sales were $807 million, down 5% overall and 4% organically. Reported diluted EPS increased to $1.86 from $1.82, while adjusted diluted EPS declined 6% to $2.06. Operating cash flow was $134 million, down 5%, and free cash flow was $118 million, down 2%.
Why did IDEX lower its full-year 2024 outlook?
The company cited uncertainty-fueled macro headwinds and project delays in industrial markets, along with continued softness in Health & Science Technologies volumes. Full-year organic sales growth is now projected to decline 1% to 2%, versus prior guidance of an increase of 0% to 2%.
What is the Mott Corporation acquisition?
On July 23, 2024, IDEX entered into a definitive agreement to acquire Mott Corporation and its subsidiaries for $1.0 billion in cash, subject to customary adjustments. Closing is expected by the end of the third quarter of 2024. Management described it as a strong fit with its businesses and strategy.
What is the outlook for the third quarter of 2024?
Third-quarter organic sales are projected to be 0% to 1% above the prior-year period. GAAP diluted EPS is expected to be $1.61 to $1.66, and adjusted diluted EPS $1.85 to $1.90.
Which segment drove the sales decline?
Health & Science Technologies, where organic net sales fell 11% on lower volumes from continued broad-based market softness that began in the second half of 2023. Price capture across markets partially offset the decline. Fluid & Metering Technologies was flat organically, and Fire & Safety/Diversified Products rose 1%.
04—Continue